AstraZeneca has gone on to announce a newly expanded manufacturing facility located in Coppell, Texas, U.S., which is going to double production of Lokelma for the advantages of patients across the U.S. as well as around the world.
This $445 million investment to expand the facility happens to be a part of the $50 billion investment in U.S. R&D as well as manufacturing by AstraZeneca over the forthcoming five years.
The Senior Vice President of Americas Supply Operations for AstraZeneca, Jim Fox, remarked that their manufacturing facility in Coppell happens to serve as both a major pillar in worldwide healthcare and, at the same time, has also played a significant role when it comes to supporting the local workforce for the past 10 years.
This expansion happens to highlight the commitment by AstraZeneca to patients and also the support for the long-term vision of Texas when it comes to scientific growth as well as innovation.
The Coppell facility of AstraZeneca happens to be the sole global manufacturing facility pertaining to Lokelma for over 50 countries across the world. The expansion of the facility is going to double production of Lokelma. Apparently, the space happens to have more than 250 people. All across its expansion and development of a new 9,000 square foot building, both novel manufacturing lines are going to be added along with upgrades so as to support the drug substance as well as drug product laboratory testing, additional manufacturing utilities, warehousing, and the administrative space.
